{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:12:05Z","timestamp":1768993925840,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:00:00Z","timestamp":1720310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Essential tremor (ET) is a chronic, progressive neurological disease that affects an estimated 7 million individuals in the United States (ie, 2.2% of the entire U.S. population). Despite its high prevalence, there are a few published studies on patterns of prescription medication use among patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim was to examine prescription drug medication use among ET patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a cross\u2010sectional study of ET patients, age \u226540, with at least 1 prescription medication fill using the Optum's de\u2010identified Clinformatics Data Mart Database from 2018 through 2019. We examined patterns of fills of key agents used to treat ET.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final sample comprised 36,839 ET patients in the United States; 89% had at least 1 prescription drug claim over a 2\u2010year period, indicating that 9 of 10 ET patients take a medication to treat their disease. For each of the 3 most frequently prescribed medications, only a modest fraction (1\/5 to 1\/4) of patients were taking that medication. Adherence to these agents was 52% to 61%. A high percentage of patients had fills for more than 1 of the main agents we studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data illustrate a need for medication in the ET population. There is only 1 FDA\u2010approved medication to treat ET, propranolol, and less than 25% of ET patients used this drug during our study period. At the same time, no single agent was utilized by more than one quarter of ET patients, adherence was low, and use of multiple agents was common. For such a common disease, the pharmacotherapeutic landscape is impoverished.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mdc3.14155","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:54:50Z","timestamp":1720400090000},"page":"1203-1211","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prescription Drug Utilization among Patients with Essential Tremor: A Cross\u2010Sectional Study of More Than 36,000 Patients"],"prefix":"10.1002","volume":"11","author":[{"given":"Kandice A.","family":"Kapinos","sequence":"first","affiliation":[{"name":"RAND Corporation  Arlington Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elan D.","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.198"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1982.tb03129.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000161852.70374.01"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/72.2.113"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.086579"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.229740"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.12.1982"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.4.805"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1184"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.03.012"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318236f0fd"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27700"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000509"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2010.07.011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120387"},{"issue":"8","key":"e_1_2_9_17_1","article-title":"Assessing comorbidity using claims data: an overview","volume":"40","author":"Klabunde CN","year":"2002","journal-title":"Med Care"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S160029"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.10.012"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02318-8"},{"key":"e_1_2_9_21_1","unstructured":"Optum's de\u2010identified Clinformatics\u00ae Data Mart Database. 2018\u20132019."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016581"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200110"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02465-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6112"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00385-w"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-140"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2011.38"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1332\/030557312X643786"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(02)00657-8"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16064"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2318003"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01733-6"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.14155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:29:24Z","timestamp":1760956164000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.14155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,7]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/mdc3.14155"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.14155","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,7]]},"assertion":[{"value":"2024-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}